This clinical-stage biotech focused on CNS disorders reported a notable insider sale amid ongoing development of its ...

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative ...

MA’s Phase 2 ZEPHYR trial in schizophrenia, with topline results expected by mid-August 2026 Last patient visit completed for ML-004’s Phase 2 IRIS trial in autism spectrum disorder, with topline ...

Appointment Comes as Tris Prepares to Submit a New Drug Application (NDA) for Cebranopadol in Moderate-to-Severe Acute Pain MONMOUTH JUNCTION, N.J., May 05, 2026 (GLOBE NEWSWIRE)-- Tris Pharma, Inc.

This clinical-stage biotech focused on CNS disorders reported a notable insider sale, as disclosed in its latest SEC filing.

US FDA approves Axsome Therapeutics’ Auvelity to treat agitation associated with dementia due to Alzheimer’s disease: New York Axsome Ther ...

Neuroimmunology has rapidly evolved as a critical field for understanding how inflammatory and immune processes shape the pathophysiology of brain ...

Preclinical AVB-406 data presented in three oral presentations demonstrate the power of the vMiXTM RNAi platform and support planned clinical initiation for Alzheimer’s disease by the end of 2026 Prec ...

Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback on use of new form ...

Neurons and white blood cells differ greatly in shape, function, and location within the body. However, researchers at the ...

Rabies is a vaccine-preventable, zoonotic, viral disease which affects the central nervous system. Rabies vaccine is given ...

VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 -- Data from eight ASGCT presentations ...